Therapy Areas: Respiratory
ALK Abello announces securing of pricing by its Japanese partner for new Japanese cedar SLIT-tablet
19 April 2018 -

ALK-Abelló A/S (ALK) (CPH:ALKB), a Danish, specialty pharmaceutical company focused on allergy and allergic asthma, announced on Wednesday that its partner for Japan, Torii Pharmaceutical Co Ltd (Torii), has agreed on a price with authorities and secured a listing on Japan's National Health Insurance reimbursement list for its sublingual allergy immunotherapy (SLIT) tablet against Japanese cedar allergy, branded CEDARCURE.

Reportedly, this listing clears the way for the forthcoming launch of CEDARCURE, which is expected to take place in the coming months.

When launched, under the terms of the partnership agreement between ALK and Torii, ALK is entitled to receive royalties on CEDARCURE sales.

According to the company, the addition of CEDARCURE to Torii's tablet range alongside the previously launched MITICURE (ACARIZAX in Europe), will mean that Torii has clinically-proven products covering Japan's two most prevalent respiratory allergies, Japanese cedar pollen and house dust mites.

Its launch will further advance ALK's strategy of completing the tablet portfolio so that it covers the world's most important respiratory allergies for all relevant ages.

CEDARCURE was developed by Torii with the support from ALK and is based on ALK's proprietary technology that underpins ALK's own tablet range. In September 2017, Torii received approval for CEDARCURE for allergy immunotherapy treatment of Japanese cedar pollinosis (allergic rhinitis) in adults and children. Reportedly, it was the first SLIT-tablet to be approved in Japan for both adult and paediatric use.

This partnership between ALK and Torii was established in 2011, covering the development, registration and commercialisation of CEDARCURE, MITICURE along with other minor products.

Login
Username:

Password: